Skip to main content

Alexey Danilov, MD

Alexey Danilov, MD
Conference Coverage
01/10/2024
At the 65th ASH Annual Meeting, Alexey Danilov, MD, analyzes the prognostic value of undetectable MRD among patients with follicular lymphoma initially treated with chemotherapy.
At the 65th ASH Annual Meeting, Alexey Danilov, MD, analyzes the prognostic value of undetectable MRD among patients with follicular lymphoma initially treated with chemotherapy.
At the 65th ASH Annual Meeting,...
01/10/2024
Oncology
Alexey Danilov, MD
Conference Coverage
10/21/2024
Alexey Danilov, MD, reviews the latest exciting developments in the chronic lymphocytic leukemia clinical research landscape, highlighting BTK and BCL2 inhibitors as well as BTK degraders.
Alexey Danilov, MD, reviews the latest exciting developments in the chronic lymphocytic leukemia clinical research landscape, highlighting BTK and BCL2 inhibitors as well as BTK degraders.
Alexey Danilov, MD, reviews the...
10/21/2024
Oncology
Alexey Danilov, MD
Conference Coverage
10/21/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Alexey Danilov, MD, participated in a debate of optimal frontline therapies for patients with chronic lymphocytic leukemia in which he argued in favor of utilizing acalabrutinib.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Alexey Danilov, MD, participated in a debate of optimal frontline therapies for patients with chronic lymphocytic leukemia in which he argued in favor of utilizing acalabrutinib.
At the 2024 Lymphoma, Leukemia &...
10/21/2024
Oncology